Threat to value of CE-marking: Eucomed wants EU strategy counterfeiting
This article was originally published in Clinica
Executive Summary
A strategy to prevent counterfeiting and piracy in medical device trade is essential, European medical technology association, Eucomed, says. The association is concerned that if this issue is not tackled, there will be a real threat to the value of the CE mark and that EU R&D will be discouraged. A legal framework is necessary that allows quick and effective action to eliminate counterfeited products from the market place and the industry must support the latest initiatives that are currently being actively pursued by the European Commission in this respect, the association asserts.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.